ASCO GI 2019: Post-Conference News on CRC - Episode 5

CRC Safety Lead-in: ASCO GI 2019 Updates

Scott Kopetz, MD, PhD, FACP; Ryan Corcoran, MD, PhD; review the design and updated safety lead-in data from the BEACON study looking at the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen also tested in the ANCHOR trial.